BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 16538189)

  • 1. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
    Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
    [No Abstract]   [Full Text] [Related]  

  • 3. Pioglitazone/glimepiride (Duetact) for diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
    [No Abstract]   [Full Text] [Related]  

  • 4. Pioglitazone + glimepiride: a combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
    [No Abstract]   [Full Text] [Related]  

  • 5. Glimepiride for NIDDM.
    Med Lett Drugs Ther; 1996 May; 38(975):47-8. PubMed ID: 8632731
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating type 2 diabetes: targeting the many causative factors.
    Sutherland JE; Hoehns JD
    J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs for type 2 diabetes.
    Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
    [No Abstract]   [Full Text] [Related]  

  • 8. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
    Ferner RE; Alberti KG
    Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
    [No Abstract]   [Full Text] [Related]  

  • 9. Pioglitazone hydrochloride/glimepiride.
    Blake EW
    Drugs Today (Barc); 2007 Jul; 43(7):487-97. PubMed ID: 17728849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
    Herman WH; Dirani RG; Horblyuk R; O'Neill MC; Kravitz B; Heise MA; Bakst A; Freed MI;
    Am J Manag Care; 2005 Apr; 11(4):273-8. PubMed ID: 15839187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.
    Thayer S; Arondekar B; Harley C; Darkow TE
    Ann Pharmacother; 2010 May; 44(5):791-9. PubMed ID: 20371759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
    MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
    [No Abstract]   [Full Text] [Related]  

  • 13. The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.
    Itakura H; Abbasi F; Lamendola C; Basina M; Reaven G
    Diabetes Obes Metab; 2008 Aug; 10(8):685-7. PubMed ID: 18476981
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin initiation in Type 2 diabetes.
    Page S
    Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
    [No Abstract]   [Full Text] [Related]  

  • 15. Pioglitazone/metformin (Actoplus met).
    Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hypoglycemic sulfamides: new pharmacologic data and practical implications].
    Blickle JF; Brogard JM
    Diabetes Metab; 1998 Jun; 24(3):276-80. PubMed ID: 9690064
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 19. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
    Tseng CH; Huang TS
    Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
    Charbonnel B
    Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.